Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 1
1983 2
1984 1
1985 3
1987 3
1989 1
1990 5
1991 3
1992 7
1993 10
1994 13
1995 26
1996 15
1997 18
1998 14
1999 24
2000 32
2001 32
2002 37
2003 49
2004 57
2005 75
2006 81
2007 105
2008 121
2009 158
2010 204
2011 248
2012 263
2013 279
2014 318
2015 355
2016 363
2017 392
2018 454
2019 639
2020 762
2021 854
2022 1030
2023 320
Text availability
Article attribute
Article type
Publication date

Search Results

6,601 results
Results by year
Filters applied: . Clear all
Page 1
AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity.
Zhang Q, Liu S, Zhang CS, Wu Q, Yu X, Zhou R, Meng F, Wang A, Zhang F, Chen S, Wang X, Li L, Huang J, Huang YW, Zou J, Qin J, Liang T, Feng XH, Lin SC, Xu P. Zhang Q, et al. Among authors: zou j. Mol Cell. 2022 Dec 1;82(23):4519-4536.e7. doi: 10.1016/j.molcel.2022.10.026. Epub 2022 Nov 15. Mol Cell. 2022. PMID: 36384137
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy.
Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, Wei Y, Wang X, Zhang L, Li X, Liu Z, Xue S, Qin C, Zeng J, Li H, Wu H, Ma H, Ellenbogen KA, Gold MR, Fan X, Zou J; LBBP-RESYNC Investigators. Wang Y, et al. Among authors: zou j. J Am Coll Cardiol. 2022 Sep 27;80(13):1205-1216. doi: 10.1016/j.jacc.2022.07.019. J Am Coll Cardiol. 2022. PMID: 36137670 Clinical Trial.
A reference human induced pluripotent stem cell line for large-scale collaborative studies.
Pantazis CB, Yang A, Lara E, McDonough JA, Blauwendraat C, Peng L, Oguro H, Kanaujiya J, Zou J, Sebesta D, Pratt G, Cross E, Blockwick J, Buxton P, Kinner-Bibeau L, Medura C, Tompkins C, Hughes S, Santiana M, Faghri F, Nalls MA, Vitale D, Ballard S, Qi YA, Ramos DM, Anderson KM, Stadler J, Narayan P, Papademetriou J, Reilly L, Nelson MP, Aggarwal S, Rosen LU, Kirwan P, Pisupati V, Coon SL, Scholz SW, Priebe T, Öttl M, Dong J, Meijer M, Janssen LJM, Lourenco VS, van der Kant R, Crusius D, Paquet D, Raulin AC, Bu G, Held A, Wainger BJ, Gabriele RMC, Casey JM, Wray S, Abu-Bonsrah D, Parish CL, Beccari MS, Cleveland DW, Li E, Rose IVL, Kampmann M, Calatayud Aristoy C, Verstreken P, Heinrich L, Chen MY, Schüle B, Dou D, Holzbaur ELF, Zanellati MC, Basundra R, Deshmukh M, Cohen S, Khanna R, Raman M, Nevin ZS, Matia M, Van Lent J, Timmerman V, Conklin BR, Johnson Chase K, Zhang K, Funes S, Bosco DA, Erlebach L, Welzer M, Kronenberg-Versteeg D, Lyu G, Arenas E, Coccia E, Sarrafha L, Ahfeldt T, Marioni JC, Skarnes WC, Cookson MR, Ward ME, Merkle FT. Pantazis CB, et al. Among authors: zou j. Cell Stem Cell. 2022 Dec 1;29(12):1685-1702.e22. doi: 10.1016/j.stem.2022.11.004. Cell Stem Cell. 2022. PMID: 36459969 Free article.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J. Wu J, et al. Among authors: zou j. BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. BMC Med. 2022. PMID: 36575513 Free PMC article. Clinical Trial.
6,601 results